SCHEMBL714032

SCHEMBL714032

CC1(C)OCC(C[O])CO1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.33
APP P05067 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3827605 0.79 APP (0.33) APP
SCHEMBL13803857 0.76 APP (0.33) CA2APP
SCHEMBL6276420 0.76 APP (0.33) CA2APP
SCHEMBL12744068 0.74 APP (0.33) APP
SCHEMBL8833046 0.74 APP (0.33) APP
SCHEMBL23671782 0.74 APP (0.33) APP
SCHEMBL3792829 0.74 CA2 (0.33) CA2APP
SCHEMBL19011946 0.74 APP (0.33) APP
SCHEMBL75036 0.74 APLNR (0.35) APP
SCHEMBL13130047 0.74 APP (0.33) APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2801574-B1 ACID ADDUCT SALTS OF SUBSTITUTED PYRIDINE COMPOUND AS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITORS DAIICHI SANKYO CO LTD (JP) 2016-07-27 EP disclosed
US-9321747-B2 Acid addition salt of substituted pyridine compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-04-26 US disclosed
US-20150299169-A1 ACID ADDITION SALT OF SUBSTITUTED PYRIDINE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-22 US disclosed
EP-2801574-A1 ACID ADDUCT SALT OF SUBSTITUTED PYRIDINE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-11-12 EP disclosed
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US disclosed
CN-101160306-B Benzimidazole compounds EISAI R&D MAN CO LTD 2011-11-02 CN disclosed
US-20090203911-A1 BENZIMIDAZOLE COMPOUND MIYAZAWA SHUHEI 2009-08-13 US disclosed
US-7425634-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-09-16 US disclosed
EP-1870409-A1 BENZIMIDAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-12-26 EP disclosed
WO-2007122686-A1 BENZIMIDAZOLE COMPOUNDS EISAI R & D MANAGEMENT CO., LTD. (JP) 2007-11-01 WO disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed
WO-2006112442-A1 BENZIMIDAZOLE COMPOUND EISAI R & D MANAGEMENT CO., LTD. (JP) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010542-A1 Benzimidazole compound HRH2, GIPR, HRH4 CA2 88/4885APP 4883/4885
US-20150299169-A1 ACID ADDITION SALT OF SUBSTITUTED PYRIDINE COMPOUND CETP, SLC10A1, MTTP CA2 251/4885APP 2323/4885
US-20090203911-A1 BENZIMIDAZOLE COMPOUND HRH2, HRH4, HRH1 CA2 60/4885APP 4879/4885
US-20070015782-A1 Benzimidazole compound HRH2, GIPR, HRH4 CA2 88/4885APP 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.